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BACKGROUND

The HIV pandemic
In the last 23 years, the Human immunodeficiency virus (HIV) infection has reached
pandemic levels with an estimate of 65 million infected people by 2006. Non-controlled HIV
infection can result in the acquired immunodeficiency syndrome (AIDS) that has caused 25
million deaths by 2006. According to the Center of Disease Control, 1.1 million people are
infected with HIV in the US. This number is predicted to considerable increase due to
antiretroviral drug treatments continue to provide a larger expectancy of life to people with HIV.
HIV proteins are the main targets of the anti-retroviral treatment. The compounds used,
block the HIV life cycle allowing the decrease of symptoms and suppression of the viral load.
These compounds are classified in three categories: protease inhibitors, nucleoside reverse
transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. These inhibitors
block the earlier step in viral infection and also arrest maturation of the virus and consequently
block infection of vulnerable cells.
HIV has a high rate of mutation, thus currently available drugs targeting viral proteins
frequently encounter drug-resistant viruses. A viable alternative to this limitation is to develop
drugs that target cellular factors required for HIV infection but that are not essential to the cell.
It is expected that the emergence of drug-resistant viruses will substantially decrease by using
drugs that target these cellular co-factors. LEDGF/p75 is the first cellular factor to be identified
that is required for HIV infection but is dispensable or normal cellular physiology [1]. Here we
propose to develop a cellular-based screening system for the identification of small-molecules
that disrupt the role of LEDGF/p75 in HIV infection.

1

HIV life cycle
HIV enters the target cell by fusion of the viral and cellular membranes mediated by the
specific interaction of viral surface glycoproteins with cellular receptors (Fig.1). Immediately
after entry, the viral RNA genome is reverse transcribed to a double-stranded DNA copy, which
associates with viral and cellular proteins forming the preintegration complex (PIC). This
complex is imported into the nucleus of the infected cell where the viral DNA is integrated into
the host chromatin (Reviewed in [2]).

Figure 1. HIV viral life cycle. After entry, the viral RNA genome is reverse transcribed and the
resulting cDNA, in association with viral and cellular proteins, forms the pre-integration
complex (PIC) that is later imported into the nucleus. The viral cDNA integrates into the host
genome and the integrated provirus is efficiently transcribed and new viral progeny produced.
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Integration of the viral DNA into the host chromatin is then catalyzed by the viral enzyme
integrase (IN), which performs two enzymatic activities essential for viral integration; 3’
processing of the linear viral genome and DNA strand transfer of the viral genome into the host
genome [2]. 3’ processing occurs soon after reverse transcription when a dinucleotide from each
HIV-1 genome end is cleaved off, leaving sticky ends on either end of the viral DNA [2]. IN’s
second enzymatic activity, DNA strand transfer, takes place after the PIC enters the nucleus and
locates a suitable integration site. Then, IN cleaves the chromosomal DNA and integrates the
viral genome. The resulting DNA recombination intermediate harbors single strand gaps that are
then repaired by the host DNA repair machinery allowing for a complete provirus formation. It is
only after integration, that proviral DNA is efficiently transcribed and the new viral progeny is
generated, making integration an essential step in HIV infection [2].
The HIV integration process is not completely understood yet.

It is though that

integration requires the concerted action of both viral and cellular proteins [3,4]. Apparently, the
integrase is the only viral protein essential for this process. Integrase interacts with the cellular
protein LEDGF/p75 and this interaction promotes HIV-1 integration as well as influences the
integration site distribution in the host chromatin [1,5,6].
Role of LEDGF/p75 in HIV-1 infection
LEDGF/p75 is a ubiquitously expressed chromatin bound protein that belongs to the
hepatoma-derived growth factor family. Chromatin binding is mediated by the functional
interaction of the PWWP domain and two AT hooks motifs, all located in the N-terminus of this
protein (Fig. 2) [7,8]. In the C-terminal region of LEDGF/p75, an evolutionarily conserved
region called the integrase binding domain (IBD) allows the interaction of LEDGF/p75 with
cellular proteins and with the viral integrase [9,10,11,12]
3
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Figure 2. LEDGF/p75 protein modular structure. The chromatin-binding domain is formed by
the functional interaction of the PWWP domain and two AT hooks motifs. The integrase binding
domain mediates the interaction of LEDGF/p75 with HIV integrase and several cellular
proteins.
Cells severely depleted of LEDGF/p75 are resistant to HIV-1 infection because a defect
in viral integration[1,6]. HIV-1 susceptibility is rescued in these cells upon re-expression of the
LEDGF/p75 wild type protein. However, expression of LEDGF/p75 mutants lacking the
chromatin binding capacity or the integrase binding domain did not rescue HIV-1
infectivity[1,6]. Based in these results, it was proposed that LEDGF/p75 acts as a molecular
tether linking the HIV-1 integrase in the pre-integration complex to the host chromatin (Fig. 3)
[1].
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Figure 3. LEDGF/p75 tethering model. Based on the study of the HIV co-factor activity of
LEDGF/p75 mutants it is postulated that chromatin bound LEDGF/p75 tethers integrase linked
to the pre-integration complex to the host chromatin facilitating viral integration.
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In addition to tethers integrase to the host chromatin, LEDGF/p75 protects the viral
enzyme from proteasomal-mediated degradation [13]. The half-life of integrase in LEDGF/p75deficient cells is importantly reduced; however, integrase mRNA levels are similar to the
observed in control cells. Importantly, integrase degradation is prevented in these cells by reexpression of LEDGF/p75 wild type or by pharmacological inhibition of the proteasome [13].
LEDGF/p75 mutants lacking the IBD, however, did not protect integrase from proteasome
degradation, indicating that this effect is dependent on the interaction of both proteins[13]
(Figure 4).
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Figure 4. LEDGF/p75 protects HIV-1 integrase from proteasomal-mediated degradation. In
the absence of LEDGF/p75, integrase is ubiquitinated and degraded through the proteasome.
The shielding effect of LEDGF/p75 requires binding to integrase.
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LEDGF/p75-Integrase interaction as an anti-HIV drug target
The interaction of LEDGF/p75 with HIV-1 integrase is a good candidate for anti-HIV
drug development. LEDGF/p75, although essential for efficient HIV replication, is dispensable
for the normal cellular physiology since cells lacking or severely deficient in LEDGF/p75
exhibited a normal phenotype in culture[1,6]. In addition, embryogenesis was not affected in
knockout mice, although musculoskeletal defects were observed in the progeny[14]. These
results strongly suggest that important host toxicity is not expected with drugs affecting the
interaction of LEDGF/p75 with HIV-1 integrase.

The structural bases of the LEDGF/p75-integrase interaction indicate that this is a
drugable interphase. Their surface of interaction is relatively small compared to other proteinprotein surface of interaction and only three amino acids in LEDGF/p75 are required for the high
binding affinity of integrase. More importantly, mutation of any of these residues to alanine
completely abolishes this protein-protein interaction[15] indicating that small-compounds are
suitable to interrupt the binding of LEDGF/p75 to HIV-1 integrase.
In summary, these results suggest that small-molecules could block the interaction of
LEDGF/p75 with HIV-1 integrase and that host toxicity is not expected with the use of these
compounds.

Small-compounds as inhibitors of the LEDGF/p75-integrase interaction.
Different approaches can be designed to inhibit the interaction LEDGF/p75-integrase
interaction. These include the use of small-compounds, small peptides, RNAi or antibodies.
However, there is a variety of advantages over using small-molecule compounds than the other
6

inhibitors. Antibodies have a quite large size that impede their intracellular distribution and in
addition are complicated and costly to produce. Small peptides are another attractive method to
use but they are unstable when used in vivo. Similarly, RNAi molecules are unstable in vivo and
the antiviral effect of LEDGF/p75-depletion requires very stringent knockdowns [1]. These
levels of depletion are difficult to be achieved in vivo with the actual technology. In addition, like
antibodies, small-peptides and RNAi are not suitable for oral administration, only by injection.
This particular feature is not convenient for HIV treatment since patients are more likely to take
oral medication than injection. Small-molecule compounds, instead, are easier to use to target
protein-protein interaction because of its small size, cellular permeability, in vivo stability and
they can interfere with protein-protein interaction efficiently; in addition they are easy and cheap
to produce [17].

High Through-put screening systems
Small-compounds inhibiting protein-protein interactions can be identified using High
through-put screening (HTS) systems. This strategy has been an important tool for drug
discovery.
HTS is a large-scale procedure in which numerous compounds are screened in a simple
biological assay that can be based on processes occurring in cells or between purified reactants.
This process is assessed in a precise and rapidly manner [18]. In order to find the best candidates
for possible drug development several steps have to be performed. A primary screening using a
biological assay and a large library of chemical compounds is performed, in which a group of
candidates are selected, called ‘hits’. A secondary screening is carried out with previously
selected hits to confirm possible candidates for a structure-activity relationship (SAR) and
7

medicinal chemistry [18]. Compounds passing secondary screenings are developed further to
reduce toxicity and improve pharmacokinetic characteristics.

8

SIGNIFICANCE

HIV-1 infection has become a continuous challenge in the finding of therapeutic drugs to
eradicate or at least decrease infection. The current anti-HIV therapy is based on the combination
of drugs that target viral proteins involved in different steps of the viral life cycle. This treatment
has substantially proven its effectiveness by extending the quality and length of life expectancy
in HIV infected individuals. However, combination of multiple drugs is mandatory to reduce the
development of drug-resistant viruses, a common outcome due to the high mutation rate of HIV
proteins. Multi-drug therapies increase the cost and toxicity of the anti-HIV treatment, severely
limiting its use worldwide and leading to the failure in preventing infection spreading.
A second generation of anti-HIV drugs targeting cellular cofactors dispensable for cells
but required for HIV infection, such as LEDGF/p75, is currently in development. These drugs
are intended to block the interaction of the cellular cofactor with its viral counterpart affecting
HIV-1 infection. Due to the low rate of mutation of cellular proteins, it is unlikely the
development of drug resistance mechanisms affecting the second generation of anti-HIV drugs.
Therefore, mono-drug regimes are suitable alternatives for these drugs.
We describe here the development a high-throughput screening (HTS) strategy to identify
small-molecules interfering with the interaction of HIV integrase - LEDGF/p75. These smallmolecules may represent starting scaffolds for therapeutic drug development.

9

SPECIFIC AIMS

Here, we report the development and validation of a HTS for small compounds inhibitory
of the HIV integrase-LEDGF/p75 interaction. The screening system is based in the ability of
LEDGF/p75 to tether integrase to chromatin [16] and protect the viral enzyme from
proteosomal-mediated degradation [13]. We generated a HEK293T-derived stable cell line
expressing eGFP-tagged HIV integrase (referred here as reporter cell line or IN-eGFPc cells).
Our rationale is that drugs inhibiting the LEDGF/p75 - integrase interaction will cause a
redistribution of IN-eGFP and a proteasome-mediated degradation of this fusion protein. These
effects were registered by measuring the subcellular distribution of IN-eGFP or the green
fluorescence levels and in the treated cells.
In order to validate this reporter cell line, we depleted LEDGF/p75 in these cells by stable
expression of a LEDGF/p75 specific shRNA. It is expected that fluorescence levels will be
significantly reduced in knockdown cells and the nuclear localization of IN-eGFP will change. In
addition, re-expression of LEDFG/p75 wild type or pharmacological inhibition of the
proteasome will rescue fluorescence levels and nuclear localization of IN-eGFP in the
LEDGF/p75-deficient cells.
The aims to be tested in this proposal are as follows:
Specific aim # 1: Generation a stable cell line expressing integrase-eGFP fusion protein (INeGFP cells)
•

Construction of a mammalian expression plasmid for the expression of HIV integraseeGFP fusion protein
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•

Generation of stable cell lines expressing HIV IN-eGFP fusion protein in HEK293T
cells.

•

Characterization of IN-eGFP cells by FACS, confocal microscopy, and immunoblotting
analyses.

Specific aim # 2: Development of a LEDGF/p75-deficient cell line in IN-eGFP cells (2LKDIN-eGFP cells)
•

Production of a lentiviral vector expressing a shRNA against LEDGF/p75

•

Generation of LEDGF/p75-deficent cells in IN-eGFP cells.

•

Rescue of integrase expression in 2LKD-IN-eGFP cells.

Specific aim # 3: Validation of the suitability of the developed reporter cell lines for drug
screening in a HTS setting
•

Drug screening of a small-compound library using the IN-eGFP reporter cell line

11

MATERIALS AND METHODS
Specific aim # 1: Generation of a stable cell line expressing integrase-eGFP fusion protein
(IN-eGFP cells)
Rationale: A reporter cell line stably expressing integrase fused to eGFP was generated. This
cell line allowed determination in real time of the subcellular distribution and the levels of
integrase proteins in cells. Drugs interfering with the LEDGF/p75-HIV integrase interaction are
expected to trigger proteasome-mediated degradation of integrase and nuclear exclusion of
integrase determining a decrease in fluorescence levels and a pancellular distribution of the
fusion protein [13,16].

•

Construction of a mammalian expression plasmid for HIV integrase-eGFP fusion
protein
The HIV-1 integrase eGFP expression plasmid was constructed by cloning an internal

ribosome entry site (IRES)-puromycin N-acetyltransferase (pac) expression cassette into a
unique BglII site in pHINeGFP (Fig. 5) [16]. IRES pac was PCR amplified from the pEFIRESp
plasmid. Correct sequence of the construct was verified by DNA sequencing.

CMV

IN-eGFP

IRES

PAC

PolyA

OriC

Kanr

Figure 5. HIV IN-eGFP expression plasmid used to develop the IN-eGFP cell line. The
expression of IN-eGFP is driven by the CMV immediate early promoter and linked through an
internal ribosome entry site (IRES) to the puromycin N-acetyltransferase (PAC) gen.
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•

Generation of stable cell lines expressing HIV IN-eGFP fusion protein in HEK293T
cells.
HEK293T cells were used for the stable expression of HIVIN-eGFP-IRES-pac. The new

constructed plasmid was transfected by the calcium phosphate method as described in [16].
Briefly, HEK293T cells were plated at 3X106 cells in a T75 flask in 12 ml of culture medium.
The expression plasmid was linearized at the prokaryotic backbone with a restriction enzyme.
Transfection media with 20ug of linearized DNA was added to the cells and incubated at 370C in
the presence of 5% CO2 and 95% humidity. After 24 hrs, culture media was changed for fresh
media with 3ug/ml puromycin antibiotic. Cells were grown in this selection medium until a
resistant culture emerges.

•

Characterization of IN-eGFP cells by FACS, confocal microscopy, and
immunoblotting analyses
Expression of IN-eGFP was evaluated in the puromycin resistant cells by fluorescence

activated cell sorting (FACS) analysis. In addition, the correct size of the fusion protein was
verified by immunoblotting with an anti-eGFP monoclonal antibody (Mab). Finally, subcellular
distribution of IN-eGFP was determined by confocal microscopy analysis.
For FACS analysis cells were harvested by trypsin treatment, washed in PBS and samples
analyzed in the flow cytometer of the Cell Culture and High throughput Screening Core Facility.
As a negative control, parental HEK293T cells were used.
For immunoblotting analysis procedures described in [16] were followed. Briefly, 106
IN-eGFP cells were lysed in 300ul of RIPA buffer (150mM Tris-HCl, pH 8.0, 150mM NaCl,
0.5% DOC, 0.1% SDS, 1% NP-40) supplemented with protease inhibitors (final concentration:
13

leupeptine 2ug/ml, aprotinin 5ug/ul, PMSF1mM, pepstatin A 1ug/ml) and centrifuged at 22,
000g for five mins at 4°C. Cellular lysates, 10ul, were resolved by SDS-PAGE and transfered
overnight to PDVF membranes at 100 mAmp at 4°C. Membrane was blocked in TBS containing
10% milk for one hour and then incubated with primary antibodies diluted in TBS-5% milk0.05% Tween-20 (antibody dilution buffer). IN-eGFP was detected with anti-eGFP monoclonal
antibody (Mab) diluted 1/4000. As a loading control, anti-GAPDH Mab was used (1/2000).
Membranes were incubated for two hrs at room temperature with, anti-eGFP, and anti-GAPDH
Mabs and then membranes were washed three times for five minutes in TBS-0.1% Tween-20
(washing buffer). Bound antibodies were detected with goat anti-mouse Igs-HRP diluted 1/2000
in antibody dilution buffer followed by chemoluminescence detection.
For confocal microscopy analysis procedures described in [16] were followed. Briefly,
cells were plated at 0.2 X106 cells in LabTek II chambered coverglasses. After 24 hrs incubation
for attachment, cells were washed 3X with PBS, fixed with 4% formaldehyde in PBS for 10 mins
at 37°C then washed once with PBS and stained with DAPI. Then, cells were analyzed for
subcellular distribution of HIV-1 IN-eGFP under the confocal microscope.

Specific aim # 2: Development of a LEDGF/p75 deficient cell line in IN-eGFP cells (2LKDIN-eGFP cells)
Rationale: It is expected that drugs interfering with the LEDGF/p75-integrase interaction will
change the subcellular localization of IN-eGFP as well as induce its degradation by the
proteasome [13,16]. In order to evaluate this hypothesis, we will deplete cellular LEDGF/p75 in
IN-eGFP cells and analyze them by FACS and confocal microscopy to determine the levels of
IN-eGFP and its subcellular distribution, respectively. Depletion of LEDGF/p75 mimic the lack
14

of LEDGF/p75 available for interaction encountered in the presence of a drug that interferes with
the interaction of this protein with integrase.

•

Production of a lentiviral vector expressing a shRNA against LEDGF/p75
LEDGF/p75 depletion of IN-eGFP was achieved by lentiviral transduction of a shRNA

specific against LEDGF/p75. This lentiviral vector integrates into the host genome a module
containing in cis an U6 small nuclear RNA promoter-driven shRNA expression cassette and a
CMV-driven mCherry fluorescent protein expression cassette. This expression system allows
selection of LEDGF/p75 knockdown cells based on their mCherry fluorescence levels[1].
Procedures described in [1] were followed for the production of the retroviral vector. Briefly,
HIV-derived vectors expressing anti-LEDGF/p75 shRNA were produced by calcium-phosphate
co-transfection of HEK293T with 15ug of pTSINcherry/p75, 15ug of pCMVΔR8.91 and 5ug of
the Vesicular Stomatitis Virus glycoprotein G (VSV-G) expression plasmid, pMD.G. Forty-eight
hours after transfection, viral supernatants were harvested and concentrated by
ultracentrifugation at 124,750g for two hours on a 20% sucrose cushion. Concentrated vectors
were used for transduction of IN-eGFP cells.

•

Generation of LEDGF/p75-deficent cells in IN-eGFP cells (2LKD-IN-eGFP cells).
IN-eGFP cells were transduced with the lentiviral vector expressing anti-LEDGF/p75

shRNA at a multiplicity of infection 300, as described before [1]. Twenty-four hrs later, the input
viral vector was washed and cells were single-cell cloned by limiting dilution cultures.
Clones expressing the highest levels of red fluorescence were selected for further analysis.
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Levels of red fluorescence were determined under the fluorescence microscope. Knockdown
levels of LEDGF/p75 were verified by immunoblotting with an anti-LEDGF Mab.

•

Rescue of integrase expression and nuclear localization in 2LKD-IN-eGFP cells.
It is expected that the eGFP fluorescence levels of IN-eGFP cells will decrease and

nuclear localization of this fusion protein will be altered following LEDGF/p75 depletion. In
other to validate further that the change in levels and subcellular distribution of IN-eGFP are due
to the lack of LEDGF/p75 and subsequently proteasome-mediated degradation of HIV integrase,
rescue experiments was performed. We expect that re-expression of LEDGF/p75 wild type or
pharmacological inhibition of the proteasome will cause a re-bound in the green fluorescence
levels of 2LKD-IN-eGFP cells associated with a nuclear re-localization of IN-eGFP.
4x105 2LKD-IN-eGFP cells were transfected with 2ug of the expression plasmid pLEDGF/p75
WT-flag using the calcium phosphate method. Transfection medium was removed the next day
and cells were analyzed twenty-four hrs later for green fluorescence levels by FACS and for
subcellular distribution of IN-eGFP by fluorescence microscopy. Additionally, integrase levels
were also determined by immunoblotting with anti-eGFP Mab. As control, a LEDGF/p75
mutant lacking the IBD was expressed in 2LKD-IN-eGFP cells. Because this mutant does not
interact with integrase, it is expected that the levels of green fluorescence will not increase in the
transfected 2LKD-IN-eGFP cells.
The effect on the green fluorescence levels of 2LKD-IN-eGFP cells of several inhibitors
targeting lysosomal function, proteasome and calpains were evaluated by FACS analysis 24 hrs
after treatment. The lysosome inhibitors include drugs that destabilize the lysosomal membrane
(ciprofloxacin, 300uM) or that increase the lysosomal pH such as Bafilomycin A1 (200nM), a
16

specific inhibitor of H+-ATPases of the vacuolar type, and lysosomotropic amines ammonium
chloride (20mM) and chloroquine (100uM). Two proteasome inhibitors were used, ALLN
(34.6uM), N-acetylleu-leu-norleucinal and MG132 (10uM), z-leu-leu-leucinal, both are peptide
aldehydes that bind to he catalytic threonine residue of the proteasome inhibiting its
chymotrypsin-like activity. In addition, PD150606 (99.4uM) that is a very specific inhibitor of
calpains 1 and 2, was used.

Specific aim # 3: Validation of the suitability of the developed reporter cell lines for drug
screening in a HTS setting.
Rationale: The suitability of IN-eGFPc cells for high throughput screening was evaluated using a
panel of eighty-eight different small molecules. In this screening, we evaluated if cells are useful
in a high throughput screening setting. End-points in this screening were sensitivity of the
reporter cell line to DMSO 1% and to the potential toxic effect of drugs used at uM
concentration.

These conditions emulated the general screening conditions of a larger small-

compound library in a HTS setting. In addition the robustness of the assay was determined
calculating the statistical parameter Z’ for IN-eGFPc and 2LKD-IN-eGFP reporter cell lines.

•

Drug screening of a compound library
The effects of eighty-eight different small-compounds in the Dimmock library (Table 1)

on IN-eGFPc cells were analyzed using the BD Pathway high-content bio-imager. End-points in
the analysis were cell morphology, cell distribution, fluorescence level, and number of live cells.
Because there are not small-compounds inhibitory of the LEDGF/p75-integrase interaction
17

commercially available, hydrogen peroxide (500µM) was used as positive control. Negative
control was DMSO 1% because this is a very common vehicle in small-compound libraries and
regular culture medium. It is relevant for the robustness of the screening system that drugs at uM
concentration or 1% DMSO do not alter the adhesion of the reporter cell line to the culture plate
or their cellular morphology.
In addition, IN-eGFPc and 2LKD-IN-eGFP treated with selected compounds were
analyzed for green fluorescence levels by FACS. Commercially available proteasome inhibitors
were used as positive control with 2LKD-IN-eGFP cells, while negative controls were 1% DMSO
and several small-compounds inhibitory of different non-proteasomal protein degradation
pathways.
IN-eGFPc cells were plated in a BD 96-well flat bottom plate at a density of 5X103 cells
per well in a total volume of 100 µl of culture media and treated the next day. Cells were
analyzed before the treatment and 3, 6 and 24hrs later using the BD Pathway high-content bioimager. Compounds were used at 1:10 dilution from the stock plate (master plate #2), with a
final concentration of 1:100 in the experimental plate. For FACS analysis, cells were plated at
1.0 X 10 5 cells per well in 500 µl of culture media in regular 24-wells tissue culture plates.
The robustness of these HTS systems were determined by calculating the Z’ factor. The
HTS system reported here can be analyzed using FACS or the BD Pathway high-content bioimager, then, we estimated the Z’ factor for these reporter systems using both methods of
analysis. Z’ was calculated according to the following equation:

18

Where σ is the standard deviation and μ is the mean of the green fluorescence levels of
cells treated with the positive (p) and the negative (n) compound. HTS systems with Z’
factors between 0.5 and 1.0 are considered excellent assays while between 0.5 and 0 are
marginal assays.
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Table 1.Dimmock library table
ID
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

ID
NC1043
NC1113
NC1114
NC1153
NC1267
NC1831
NC1876
NC1910
NC1949
NC2066
NC2067
NC2071
NC2072
NC2081
NC2085
NC2089
NC2090
NC2091
NC2094
NC2095
NC2099
NC2102
NC2106
NC2107
NC2140
NC2154
NC2162
NC2175
NC2215
NC2216
NC2217
NC2311
NC2312
NC2313
NC2315
NC2316
NC2317
NC2320
NC2321
NC2322
NC2324
NC2325
NC2326
NC2329

STOCK Conc.
[mM]
5.0
10.0
50.0
25.0
50.0
25.0
5.0
50.0
5.0
50.0
10.0
2.5
1.0
50.0
25.0
25.0
10.0
50.0
5.0
10.0
5.0
50.0
50.0
50.0
2.5
50.0
25.0
25.0
50.0
50.0
50.0
50.0
10.0
10.0
5.0
25.0
50.0
50.0
50.0
50.0
50.0
25.0
50.0
50.0

1:10 DIL
Conc. [mM]
0.5
1
5
2.5
5
2.5
0.5
5
0.5
5
1
0.25
0.1
5
2.5
2.5
1
5
0.5
1
0.5
5
5
5
0.25
5
2.5
2.5
5
5
5
5
1
1
0.5
2.5
5
5
5
5
5
2.5
5
5

ID
No.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
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ID
NC2361
NC2362
NC2365
NC2366
NC2384
NC2385
NC2386
NC2387
NC2388
NC2389
NC2390
NC2391
NC2392
NC2393
NC2394
NC2395
NC2396
NC2397
NC2398
NC2399
NC2400
NC2401
NC2402
NC2403
NC2404
NC2405
NC2406
NC2407
NC2408
NC2409
NC2410
NC2411
NC2412
NC2413
NC2414
NC2415
NC2416
NC2417
NC2418
NC2419
NC2420
NC2421
NC2422
NC2423

STOCK
Conc.
[mM]
10.0
5.0
10.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
50.0
1.0
50.0
10.0
50.0
10.0
10.0
50.0
50.0
50.0
10.0
10.0
25.0
2.5
50.0
10.0
0.5
1.0
50.0
0.5
0.5
2.5
10.0
2.5
2.5
10.0
5.0
2.5
0.1
0.1
1.0
50.0

1:10 DIL
Conc. [mM]
1
0.5
1
5
5
5
5
5
5
5
5
5
5
0.1
5
1
5
1
1
5
5
5
1
1
2.5
0.25
5
1
0.05
0.1
5
0.05
0.05
0.25
1
0.25
0.25
1
0.5
0.25
0.01
0.01
0.1
5

RESULTS
Specific aim # 1: Generation of a stable cell line expressing integrase-eGFP fusion protein
(IN-eGFP cells)
IN-eGFP cell line was successfully generated by stable transfection of the pIN-eGFPIRES-pac expression plasmid. A robust polyclonal cell population was obtained after two weeks
of selection in puromycin. High levels of green fluorescence were detected by FACS analysis of
these cells (Fig.6) and, as expected[16], integrase-eGFP was detected in the nuclear
compartment of the cells by confocal microscopy analysis (Fig.7).

Stable expression of
HIV integrase-eGFP
HEK293

PI

HEK293

IN-eGFP

PI

IN-eGFP

eGFP

eGFP

Figure 6. FACS analysis of IN-eGFP cells. High levels of green fluorescence were detected in
cells stably transfected with the expression plasmid encoding IN-eGFP-IRES-PAC (Fig. 5).
Parental HEK293T cells were sued as a negative control.
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eGFP

DAPI

Chromatin

LEDGF/p75
tether

DIC

Integrase

Figure 7. Confocal microscopy analysis of IN-eGFP cells. IN-eGFP was localized to the
nuclear compartment of these cells.

Specific aim # 2: Development of a LEDGF/p75 deficient cell line in IN-eGFP cells (2LKD-INeGFP cells)
The screening strategies that we were planning for the identification of inhibitors of the
LEDGF/p75-integrase interaction are based on the capacity of LEDGF/p75 to tether integrase to
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the chromatin and to shield it from proteasomal degradation. Our rational is that drugs interfering
with this protein-protein interaction will determine a pancellular redistribution of the fusion
protein and trigger its degradation causing a decrease in the green fluorescence levels of the INeGFP cells. Because small-compounds inhibitory of the LEDGF/p75-integrase interaction are
not commercially available, we used RNAi methodology to validate our screening system.
LEDGF/p75-specific and control shRNAs were delivered in IN-eGFP cells by retroviral
transduction. The retroviral-delivered shRNA expression cassette also contains in cis a
transcription unit expressing monomeric cherry fluorescence protein (mCherry). Therefore, INeGFP transduced cells also expressed mCherry. In contrast with the green fluorescence protein
that is linked to integrase and its total levels directly depend on LEDGF/p75 availability,
mCherry levels are absolutely LEDGF/p75-independent and can inform about the cellular
homeostasis. Then, we propose to detect cherry fluorescence by FACS or confocal microscopy
analysis during HTS of small-compounds as a counter-screening method to detect compounds
causing a global decrease in protein synthesis; i.e. toxic compounds. The advantage of this
strategy is that the counter screening does not require additional manipulation and can be done
concomitantly with the primary screening.

Generation of 2LKD-IN-eGFP cells
2LKD-IN-eGFP cells were efficiently generated by lentiviral transduction of IN-eGFP
cells. Several single-cell clones expressing high levels of cherry fluorescence were isolated and
analyzed further for LEDGF/p75 and green fluorescence levels.
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LEDGF/p75 was undetectable in 2LKD-IN-eGFP cells by sensitive immunoblots (Fig. 8)
and this correlated with a decrease in green fluorescence levels as compared to IN-eGFP cells
expressing wild type levels of LEDGF/p75 (Fig. 9).

Stable expression of LEDGF/p75specific siRNA
LEDGF/p75+

LEDGF/p75-

LEDGF/p75
GAPDH
LEDGF/p75-

+

LEDGF/p75
Number of singlecell clones analyzed

2

3

Figure 8. LEDGF/p75 levels in 2LKD-IN-eGFP and IN-eGFP cells. LEDGF/p75 levels were
analyzed by immunoblotting in three different single-cell clones derived from IN-eGFP cells
transduced with a lentivirus expressing a shRNA specific to LEDGF/p75 (2LKD-IN-eGFPcells)
or two different single-cell clones derived from control IN-eGFP cells. GAPDH was determined
in the same immunoblot membrane as a loading control.
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16

10

Figure 9. FACS analysis of IN-eGFP- and 2LKD-IN-eGFP-derived single-cell clones. Green
fluorescence levels were routinely higher in IN-eGFP-derived (LEDGF/p75+) than in 2LKD-INeGFP-derived single-cell clones (LEDGF/p75-).

Characterization of 2LKD-IN-eGFP cells
In addition to a reduction in the green fluorescence levels of IN-eGFP cells, LEDGF/p75depletion caused a redistribution of the subcelular localization of IN-eGFP. This fusion protein
localized pancellularly in 2LKD-IN-eGFP (Fig. 10) in marked contrast with the exclusively
nuclear localization observed in the parental IN-eGFP cells (Fig. 7 and 10).
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LEDGF/p75+
IN-eGFP cells

shRNA antiLEDGF/p75

LEDGF/p752LKD-IN-eGFP cells

Figure 10. Sub-cellular distribution of eGFP tagged integrase in IN-eGFP and 2LKD-INeGFP cell lines. The nuclear localization of the fusion protein in the LEDGF/p75+ cells INeGFP cells was lost after efficient knockdown of LEDGF/p75 (2LKD-IN-eGFP cells).
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Transient expression of LEDGF/p75 wild type rescued the green fluorescence levels in
2LKD-IN-eGFP cells (Fig.12 and 13) and redistribute IN-eGFP to the nuclear compartment of
cells in interphase and to chromosomes in cells undergoing mitosis (Fig. 11-ii). However, a
LEDGF/p75 mutant lacking the IBD failed to produce any of these effects indicating that
LEDGF/p75-integrase interaction was required (Figs.11-iii, 12 and 13).

(i) None

(ii) LEDGF/p75 WT

(iii) LEDGF/p75 ΔIBD

Figure 11. Effect of LEDGF/p75 expression in the localization of IN-eGFP in 2LKD-INeGFPcells. Wild type LEDGF/p75, but not the ΔIBD mutant, can rescue nuclear and
chromosomal localization of IN-eGFP in 2LKD-IN-eGFP cells, as determined by confocal
microscopy analysis.
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1 Non transfected
2 LEDGF/p75 ΔIBD
3 LEDGF/p75 wt
Figure 12. Green fluorescence levels of 2LKD-IN-eGFP cells after re-expression of
LEDGF/p75 WT and ΔIBD mutant. Wild type LEDGF/p75, but not the ΔIBD mutant, can
increase the green fluorescence levels of 2LKD-IN-eGFP cells, as determined by FACS analysis.
Levels of re-expressed LEDGF proteins were verified by immunoblotting.

28

Non transfected

LEDGF/p75 ΔIBD

LEDGF/p75 wt

UV

Visible

Figure 13.

Green fluorescence levels of 2LKD-IN-eGFP cells after re-expression of

LEDGF/p75 WT and ΔIBD mutant. Wild type LEDGF/p75, but not the ΔIBD mutant, can
increase the green fluorescence levels of 2LKD-IN-eGFP cells, as determined by fluorescence
microscopy.

Effect of proteasome inhibitors on the green fluorescence levels of 2LKD-IN-eGFP cells
Inhibition of the proteasome using MG132 or ALLN prevent IN degradation in the
absence of LEDGF/p75 in 2LKD-IN-eGFP cells (Fig. 14 and 16). An increase of 2-fold was
recorded using 50uM,

25 uM and 10 uM concentration of MG132. However, 2LKD-IN-eGFP

cells treated with four different lysosome inhibitors, Ciproflaxacin, Ammonium Chloride,
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Bafilomycin and Chloroquine or with the calpains 1 and 2 inhibitor PD150606 did not rescue the
expression of IN-eGFP (Fig. 14 and 16).

Figure 14. Effect of proteasome and lysosome inhibitors on green fluorescence levels of
2LKD-IN-eGFP cells. A two-fold increase in fluorescence levels was detected in 2LKD-IN-eGFP
cells treated with the proteasome inhibitor MG132. On the other hand, the fluorescence levels of
2LKD-IN-eGFP cells did not vary after treatment with several lysosome inhibitors.
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Specific aim # 3: Validation of the suitability of the developed reporter cell lines for drug
screening in a HTS setting.
Z’-factors.
In order to validate the robustness of these two assays in a HTS setting we calculated the
Z’-factor having as read-outs green fluorescence levels using the BD Pathway confocal
microscope and the FACS.
To calculate the Z’-factor of the HTS system developed for identification of inhibitors of
the LEDGF/p75-integrase interaction based in IN-eGFPc cells we used as positive control
hydrogen peroxide. A small-compound affecting this protein-protein interaction is not
commercially available yet. Hydrogen peroxide is highly cytotoxic and green fluorescence levels
are expected to be importantly diminished in treated cells. As negative control we used DMSO
1% since compounds in chemical libraries used for HTS are commonly dissolved in DMSO.
Cells treated with these compounds were evaluated after 3 and 6 hrs by confocal microscopy in
the BD Pathway (Table 2).
Using the formula described in Material and Methods, we calculated that the Z’-factor for
this HTS system using the BD pathway confocal microscope was 0.36. This Z’-factor value is
indicative of a marginal HTS system. The main reason for these results was that the treated cells
were partially detached from the assay plate and formed aggregates. A typical result is presented
in figure 15 were cells are shown before and 3hrs after treatment with hydrogen peroxide,
DMSO and compound B08. Although the cells were spread and attached to the plate before
treatment, 3hrs after treatment these cells detached and aggregated. Confocal microscopic
examination of the treated cells using BD pathway indicated that hydrogen peroxide treatment
markedly reduced green fluorescence levels of IN-eGFPc cells as compared to DMSO treatment.
However, because the BD Pathway software used for calculation is based on cellular
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morphology, data processing showed only a modest 1.78 fold decrease. In addition, standard
deviation of this analysis was between 4.4% and 8.8 % the mean green fluorescence value
reducing the robustness of the assay. Therefore we decided not to continue this read-out strategy
and instead use FACS analysis.
Then, the effect of hydrogen peroxide and DMSO treatment on the green fluorescence
levels of IN-eGFP cells was analyzed by FACS. Using this read-out a Z’-factor indicative of an
exceptional assay for HTS was obtained.
Based on these results with the reporter cell line IN-eGFPc we decided to use FACS
analysis to calculate the Z’-factor of the HTS proposed for the identification of proteasome
inhibitors. As positive controls two proteasome inhibitors, MG132 and ALLN, were used while
DMSO was used as negative control. 2LKD-IN-eGFP cells were treated with the drugs described
above and 24 hrs later green fluorescence levels were determined by FACS (Fig. 16). Similar to
the HTS described above, the Z’-factor of this assay was 0.62 and 0.57 for the MG132/DMSO
and ALLN/DMSO pairs, respectively. These data indicate this assay as a very robust screening
system.
Screening of a small chemical library
A preliminary high-throughput screening of 88 compounds was conducted with IN-eGFP
cells using a drugs in the uM range of concentration. Readouts were performed with the the BD
Pathway confocal microscope 3 hrs, 6 hrs and 24 hrs after treatment. Screening of this chemical
library with the BD pathway confocal microscope encounter the technical limitations described
above when the Z’-factor was calculated; therefore we further concluded that the BD Pathway is
not the optimal read-out system for this HTS.
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Table 2. Mean and standard deviation of green fluorescence levels of IN-eGFP cells treated with
hydrogen peroxide and DMSO.
Time points
3 hours
6 hours
Mean
Standard deviation

Hydrogen peroxide
Positive control
881.901
999.874
940.887
83.42

DMSO
Negative control
1630.677
1735.428
1683.053
74.07

Figure 15. BD pathway confocal microscopy analysis of IN-eGFP cells. Note that cells
detach and aggregate after treatment.
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Figure 16. Green fluorescence levels in 2LKD-IN-eGFP cells treated with different

compounds. Cells were treated with the indicated compounds and 24 hrs later their green
fluorescence was analyzed by FACS.
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DISCUSSION
Here we report the development and validation of two different HTS system. These are
homogeneous cell-based assays and the read-outs are green and cherry fluorescence levels. Our
results indicated that these systems will be useful to identify small-compounds antagonist the
LEDGF/p75-HIV integrase interaction or compounds inhibiting the proteasome.
The cells used in these reporter systems are derived from HEK293T cells. They were
engineered to stably express HIV-1 integrase C-terminally tagged with eGFP as well as the
monomeric cherry fluorescence protein (mCherry). The use of these spectroscopically different
fluorescence proteins allows to concomitantly measure in real time the levels of HIV-1 integrase
(green fluorescence) as well as the healthy of the reporter cells (cherry fluorescence).
The screening system proposed for the identification of inhibitors of the LEDGF/p75integrase interaction use IN-eGFP cells. Based in reported observations, we expect that drugs
blocking the interaction of LEDGF/p75 with integrase will lead to integrase degradation and a
change in its subcellular distribution. Hence, it is predictable that these drugs will reduce the
green fluorescence levels in IN-eGFP cells. However, toxic drugs, that globally affect the
cellular homeostasis, will also lead to an unspecific reduction of the green fluorescence in these
cells. To exclude these toxic drugs earlier in the HTS campaign we propose to determine during
the primary screening mCherry levels in the treated IN-eGFP cells. Only drugs that reduce the
green fluorescence but that do not affect cherry fluorescence levels will be considered specific
hits that will be selected for secondary screenings.
To validate this screening system we demonstrate that disruption of LEDGF/p75integrase interaction lead to a specific decrease in green fluorescence levels in IN-eGFP cells.
Because small compounds inhibitory of this protein-protein interaction are not commercially
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available yet, we stably depleted LEDGF/p75 in IN-eGFP cells using a specific shRNA
generating the 2LKD-IN-eGFP reporter cells. LEDGF/p75 depletion was achieved by lentiviral
transduction of IN-eGFP cells with a vector that inserted in the host genome a bi-cistronic
cassette containing in cis a LEDGF/p75-specific or control shRNA-expression unit and an
immediately early CMV promoter-driven mCherry cassette. Using this strategy, we
demonstrated that LEDGF/p75 depletion decreased the green fluorescence levels in IN-eGFP
cells and that the IN-eGFP protein redistributed from an exclusively nuclear localization to a
pancellular distribution. To further demonstrate the specificity of these effects, both green
fluorescence levels and nuclear localization of IN-eGFP protein were rescued by transient
transfection of LEDGF/p75 in 2LKD-IN-eGFP cells. Importantly, transient expression of a
LEDGF/p75 mutant lacking IBD did not exhibit this rescue capability, further indicating that
LEDGF/p75-integrase interaction was required.
Finally, we demonstrated the robustness of this HTS system when FACS analysis was
used to detect green fluorescence levels. Instead, a high content image analysis was not suitable
for screening showing poor reliability.
The HTS system that we have developed for the identification of inhibitors of the
LEDGF/p75-integrase interaction offers several advantages compared to other reported HTS
systems. Reported assays are alpha-screens that are homogeneous, cell-free systems that employ
recombinant proteins. Different from these other screening systems, our assay will select only
cellular permeable compounds that can interfere with the LEDGF/p75-integrase interaction in
the intracellular environment. These are very important qualities that allow prioritizing at the
primary screening only physiologically relevant hits. In addition, our reporter incorporates a
counter-screening assay to exclude toxic compounds that is absent in the reported non-cell based
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HTS systems. This counter-assay can be run concomitantly with the primary screening without
extra manipulation. These are desired characteristics of HTS systems that diminish time and cost
of the assay. Therefore, our system represents a clear advantage over other currently used HTS
assays for the identification of inhibitors of the LEDGF/p75-integrase interaction.
The second HTS system developed is useful for the identification of small-compounds
inhibitory of the proteasome pathway. In the absence of LEDGF/p75, integrase is ubiquitinylated
and degraded through the proteasome. This phenomenon was observed in IN-eGFP-derived cells
were LEDGF/p75 was severely depleted, 2LKD-IN-eGFP cells. It is expected that drugs
interfering with the proteasome will increase the green fluorescence levels in 2LKD-IN-eGFP
cells without altering mCherry levels. In order to validate this screening system we treated 2LKDIN-eGFP cells with different drugs inhibitory of the proteasome, the lysosome and the calpains.
Importantly, only proteasome inhibitors markedly increased green fluorescence levels in these
cells, demonstrating the specificity of this reporter system. Robustness of this HTS system was
also determined to be excellent (Z’-factor ~0.6) when cells were subject to FACS analysis.
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CONCLUSION

We have developed and validated two robust HTS assays. The first assay is useful for
identification of small-compounds antagonist of the LEDGF/p75-HIV integrase interaction while
the second assay can identify inhibitors of the proteasome pathway. The most important features
of these assays are:

¾ Cell-based. Different from in vitro screening systems, cell-based assays allow selection
of compounds that are cell permeable, that reach the target intracellular compartments
and that can disrupt physiological interaction occurring in the intracellular
microenvironment. Therefore, using cell-based assays pharmacologically relevant
compounds are selected reducing the number of unnecessary hits entering the secondary
screening.

¾ Counter-screen build up in the system and using the same read-out that the primary
screening. The Counter-screening will exclude toxic compounds. The fact that the
developed HTS systems allow to conduct the counter-screening at the same time that the
primary screening and without further manipulation facilitates the selection of relevant
hits reducing time and price of the screening.

¾ Homogeneous assay. The developed HTS systems are mix-and-read assays that facilitate
the screening campaign by reducing manipulation and time.
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¾ Robust assays. Z’-factor calculated for these assays are above 0.5 indicating an excellent
signal-to-noise ratio.

Further work is necessary now to develop secondary and tertiary assays for these primary
HTS systems.
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